GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
62.32
-4.53 (-6.78%)
At close: May 1, 2025, 4:00 PM
62.73
+0.41 (0.66%)
After-hours: May 1, 2025, 5:55 PM EDT
Company Description
GeneDx Holdings Corp., a genomics company, provides genetic testing services.
It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
The company is headquartered in Stamford, Connecticut.
GeneDx Holdings Corp.
Country | United States |
Founded | 2017 |
Industry | Diagnostics & Research |
Sector | Healthcare |
Employees | 1,000 |
CEO | Katherine Stueland |
Contact Details
Address: North Tower, 6th Floor Stamford, Connecticut 06902 United States | |
Phone | 888 729 1206 |
Website | genedx.com |
Stock Details
Ticker Symbol | WGS |
Exchange | NASDAQ |
Stock Type | Common Stock |
Share Class | Class A Shares |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001818331 |
CUSIP Number | 81663L200 |
ISIN Number | US81663L2007 |
Employer ID | 85-1966622 |
SIC Code | 8000 |
Key Executives
Name | Position |
---|---|
Katherine A. Stueland | President, Chief Executive Officer and Director |
Kevin Feeley CPA | Chief Financial Officer |
Dr. Bryan M. Dechairo Ph.D. | Chief Operating Officer |
Eric Olivares Ph.D. | Chief Product and Technology Officer |
Heidi C. Chen J.D. | Chief Legal Officer |
Jami Biliboaca | Head of People Strategy |
Paul Kruszka FACMG, M.D., M.P.H. | Chief Medical Officer |
Melanie Duquette | Chief Growth Officer |
Sabrina Dunbar | Chief of Staff |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 30, 2025 | ARS | Filing |
Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
Apr 30, 2025 | 10-Q | Quarterly Report |
Apr 30, 2025 | 8-K | Current Report |
Apr 29, 2025 | 144 | Filing |
Apr 29, 2025 | 144 | Filing |
Apr 16, 2025 | 8-K | Current Report |
Apr 14, 2025 | 144 | Filing |
Apr 9, 2025 | 144 | Filing |